Citigroup
PRAX icon

Citigroup’s Praxis Precision Medicines PRAX Stock Holding History

Citigroup’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,200
Closed -$386K – 5845
2025
Q1 		$386K Sell
10,200
-66,300
-87% -$4.14M ﹤0.01% 3812
2024
Q4 		$5.89M Buy
76,500
+600
+0.8% +$43.4K ﹤0.01% 1793
2024
Q3 		$4.37M Buy
+75,900
New +$4.1M ﹤0.01% 1967

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citigroup's PRAX Position: Q2 2026 in Review

Citigroup increased its Praxis Precision Medicines (PRAX) stake by 318% in Q2 2026, buying an estimated $5.68M and bringing the position to 23,599 shares worth $7.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1779.

Citigroup first reported a position in PRAX in Q4 2020 and has held it in 23 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Citigroup held 23,599 shares of Praxis Precision Medicines worth $7.9M as of Q2 2026.
  • Citigroup bought 17,953 Praxis Precision Medicines shares in Q2 2026, an estimated $5.68M.
  • Praxis Precision Medicines made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1779 holding.
  • Citigroup first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 23 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.